Aligos Therapeutics Inc (ALGS)
0.818
-0.01
(-1.33%)
USD |
NASDAQ |
Apr 25, 16:00
0.8012
-0.02
(-2.05%)
After-Hours: 20:00
Aligos Therapeutics Cash from Investing (Quarterly): -0.007M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.007M |
| September 30, 2023 | -0.009M |
| June 30, 2023 | 25.00M |
| March 31, 2023 | 19.99M |
| December 31, 2022 | 11.60M |
| September 30, 2022 | 32.48M |
| June 30, 2022 | -9.976M |
| March 31, 2022 | -60.40M |
| Date | Value |
|---|---|
| December 31, 2021 | -16.48M |
| September 30, 2021 | -0.04M |
| June 30, 2021 | 9.848M |
| March 31, 2021 | 9.693M |
| December 31, 2020 | 14.94M |
| September 30, 2020 | 26.66M |
| June 30, 2020 | 14.93M |
| March 31, 2020 | -23.77M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-60.40M
Minimum
Mar 2022
32.48M
Maximum
Sep 2022
3.404M
Average
9.770M
Median
Cash from Investing (Quarterly) Benchmarks
| Mirum Pharmaceuticals Inc | -2.00M |
| CEL-SCI Corp | -0.0649M |
| AIM ImmunoTech Inc | -0.214M |
| IGC Pharma Inc | -0.061M |
| NovaBay Pharmaceuticals Inc | -0.002M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -22.66M |
| Cash from Financing (Quarterly) | 87.94M |
| Free Cash Flow | -79.02M |
| Free Cash Flow Per Share (Quarterly) | -0.3018 |
| Free Cash Flow to Equity (Quarterly) | -22.66M |
| Free Cash Flow to Firm (Quarterly) | -21.20M |
| Free Cash Flow Yield | -188.7% |